Could a single injection after ankle surgery ward off arthritis?

NCT ID NCT04589611

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study tests whether a drug called amobarbital, injected into the ankle joint during fracture repair surgery, can prevent post-traumatic osteoarthritis. The trial involves 5 adults aged 18–60 with severe ankle fractures. The main goal is to check safety, but researchers will also look for signs that the treatment protects cartilage and reduces joint inflammation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
amobarbital (with hyaluronic acid)
What this could lead to
If successful, this approach could reduce the risk of arthritis after severe ankle fractures, potentially preserving joint function and avoiding long-term pain.
What could go wrong
This is a very early, small trial with only 5 participants, primarily testing safety. The treatment may not prove effective, and amobarbital could cause side effects or fail to prevent arthritis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Iowa

    Iowa City, Iowa, 52240, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.